EUCTR2007-005157-33-AT进行中（未招募）不适用
A randomized observer and subject masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationMulticenter Anti VEGF Trial in Austria (MANTA) - MANTA
udwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie0 个研究点目标入组 320 人开始时间: 2008年4月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 50 years
- •Active primary or recurrent subfoveal lesion with CNV secondary to AMD, activity to be proven by fluorescein angiography as described previously (Rosenfeld et al. 2006).
- •Best corrected visual acuity assessed using ETDRS charts of 20/40 to 20/320 in the study eye.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior treatment with any intravitreal drug in the study eye
- •Prior treatment with verteporfin photodynamic therapy in the study eye
- •Prior treatment with systemic bevacizumab
- •Prior treatment with any intravitreal durg or verteprofin photodynamic therapy in the nonstudy eye within the 3 moths before the study entry
- •Laser photocoagulation within 1 month before study entry in the study eye
- •Previous participation in any clinical trial within 1 month before the entry of the study
- •Subfoveal fibrosis or atrophy in the study eye
- •CNV in either of the two eye due to causes other than AMD such as histoplasmosis or pathologica myopia
- •Retinal pigment epithelial tear involving the macula in the study eye
- •Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 12 month study period or that could contribute to a loss of best corrected visual acuity over the 12 months study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). The decision on exclusion is to be based on the opinion of the local principal investigator.
- •Active intraocular inflammation
- •Vitreous hemorrhage in the study eye
- •History of rhematogenous retinal detachment or stage 3 or 4 macula hole in the study eye
- •History of idiopathic or autoimmune-asscoaited uveitis in either eye
- •Infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye
- •Aphakia or absence of the posterior capsule in the study eye
- •Intraocular surgery in the study eye within 2 months before the entry of the study
- •History of corneal transplant in the study eye
- •History of myocardial infaraction and/or stroke
- •History of any ocular or systemic disease that according to the opinion of the local principal investiagtor may affect the interpretation of the study results or render the subject at high risk for treatment complications
- •History of allergy to fluorescein, not amendable with diphenhydramine
- •Inability to comply with study procedures
研究者
相似试验
尚未招募
4 期
A randomised controlled observer blinded trial comparing a standard technique with an ultrasound technique for axillary blockade in teaching hospitalsSURGICALSurgery - Surgical techniquesACTRN12605000750684St Vincents Hospital, Melbourne450
已完成
4 期
A Randomized, pilot study, subject-masked comparison of visual function after bilateral implantation of Presbyopia-correcting IOLsbilateral cataractstare10047518NL-OMON34149Alcon Laboratories15
已完成
不适用
Terbinafine Compared to Griseofulvin in Children With Tinea CapitisPER-038-04OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
1 期
Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato para pacientes con artritis reumatoide activa (AR)A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoid arthritis (RA).EUCTR2005-003694-25-ESF. Hoffmann-La Roche Ltd200
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855BronchiectasisEUCTR2019-002840-26-DEovartis Pharma AG72